Modular Signature of Long Non-coding RNA Association Networks As a Prognostic Biomarker in Lung Cancer

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2021 Dec 7

PMID 34872564

Citations 4

Authors

Albert Li

Wen-Hsuan Yu

Chia-Lang Hsu

Hsuan-Cheng Huang

Hsueh-Fen Juan

Affiliations

Soon will be listed here.

Abstract

Background: Increasing amount of long non-coding RNAs (lncRNAs) have been found involving in many biological processes and played salient roles in cancers. However, up until recently, functions of most lncRNAs in lung cancer have not been fully discovered, particularly in the co-regulated lncRNAs. Thus, this study aims to investigate roles of lncRNA modules and uncover a module-based biomarker in lung adenocarcinoma (LUAD).

Results: We used gene expression profiles from The Cancer Genome Atlas (TCGA) to construct the lncRNA association networks, from which the highly-associated lncRNAs are connected as modules. It was found that the expression of some modules is significantly associated with patient's survival, including module N1 (HR = 0.62, 95% CI = 0.46-0.84, p = 0.00189); N2 (HR = 0.68, CI = 0.50-0.93, p = 0.00159); N4 (HR = 0.70, CI = 0.52-0.95, p = 0.0205) and P3 (HR = 0.68, CI = 0.50-0.92, p = 0.0123). The lncRNA signature consisting of these four prognosis-related modules, a 4-modular lncRNA signature, is associated with favourable prognosis in TCGA-LUAD (HR = 0.51, CI = 0.37-0.69, p value = 2.00e-05). Afterwards, to assess the performance of the generic modular signature as a prognostic biomarker, we computed the time-dependent area under the receiver operating characteristics (AUC) of this 4-modular lncRNA signature, which showed AUC equals 68.44% on 336th day. In terms of biological functions, these modules are correlated with several cancer hallmarks and pathways, including Myc targets, E2F targets, cell cycle, inflammation/immunity-related pathways, androgen/oestrogen response, KRAS signalling, DNA repair and epithelial-mesenchymal transition (EMT).

Conclusion: Taken together, we identified four novel LUAD prognosis-related lncRNA modules, and assessed the performance of the 4-modular lncRNA signature being a prognostic biomarker. Functionally speaking, these modules involve in oncogenic hallmarks as well as pathways. The results unveiled the co-regulated lncRNAs in LUAD and may provide a framework for further lncRNA studies in lung cancer.

Citing Articles

Elucidating the Influence of MPT-driven necrosis-linked LncRNAs on immunotherapy outcomes, sensitivity to chemotherapy, and mechanisms of cell death in clear cell renal carcinoma.

Huang J, Liu M, Chen H, Zhang J, Xie X, Jiang L Front Oncol. 2024; 13:1276715.

PMID: 38162499 PMC: 10757362. DOI: 10.3389/fonc.2023.1276715.

The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.

Huang H, Wu W, Lu Y, Pan X J Thorac Dis. 2022; 14(10):4055-4072.

PMID: 36389308 PMC: 9641337. DOI: 10.21037/jtd-22-1185.

Recent Major Transcriptomics and Epitranscriptomics Contributions toward Personalized and Precision Medicine.

Mubarak G, Zahir F J Pers Med. 2022; 12(2).

PMID: 35207687 PMC: 8877836. DOI: 10.3390/jpm12020199.

LncTx: A network-based method to repurpose drugs acting on the survival-related lncRNAs in lung cancer.

Li A, Huang H, Huang H, Juan H Comput Struct Biotechnol J. 2021; 19:3990-4002.

PMID: 34377365 PMC: 8319574. DOI: 10.1016/j.csbj.2021.07.007.

References

Fuxman Bass J, Diallo A, Nelson J, Soto J, Myers C, Walhout A . Using networks to measure similarity between genes: association index selection. Nat Methods. 2013; 10(12):1169-76. PMC: 3959882. DOI: 10.1038/nmeth.2728. View

Ma B, Li Y, Ren Y . Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer. Cancer Med. 2019; 9(1):335-349. PMC: 6943089. DOI: 10.1002/cam4.2621. View

Guney E, Menche J, Vidal M, Barabasi A . Network-based in silico drug efficacy screening. Nat Commun. 2016; 7:10331. PMC: 4740350. DOI: 10.1038/ncomms10331. View

Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View

Kim T, Jeon Y, Cui R, Lee J, Peng Y, Kim S . Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. J Natl Cancer Inst. 2015; 107(4). PMC: 4402359. DOI: 10.1093/jnci/dju505. View

van Dam S, Vosa U, van der Graaf A, Franke L, de Magalhaes J . Gene co-expression analysis for functional classification and gene-disease predictions. Brief Bioinform. 2017; 19(4):575-592. PMC: 6054162. DOI: 10.1093/bib/bbw139. View

Wu C, Hsu C, Lu P, Lin W, Juan H, Huang H . Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules. Sci Rep. 2016; 6:35939. PMC: 5081511. DOI: 10.1038/srep35939. View

Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A . Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature. 2007; 445(7128):666-70. DOI: 10.1038/nature05519. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

10.

Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019; 5(12):1749-1768. PMC: 6777271. DOI: 10.1001/jamaoncol.2019.2996. View

11.

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

12.

Feldstein O, Nizri T, Doniger T, Jacob J, Rechavi G, Ginsberg D . The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage. Mol Cancer. 2013; 12(1):131. PMC: 4176120. DOI: 10.1186/1476-4598-12-131. View

13.

Hart J, Roberts T, Weinberg M, Morris K, Vogt P . MYC regulates the non-coding transcriptome. Oncotarget. 2015; 5(24):12543-54. PMC: 4350361. DOI: 10.18632/oncotarget.3033. View

14.

Hirota K, Miyoshi T, Kugou K, Hoffman C, Shibata T, Ohta K . Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs. Nature. 2008; 456(7218):130-4. DOI: 10.1038/nature07348. View

15.

Wu X, Sui Z, Zhang H, Wang Y, Yu Z . Integrated Analysis of lncRNA-Mediated ceRNA Network in Lung Adenocarcinoma. Front Oncol. 2020; 10:554759. PMC: 7523091. DOI: 10.3389/fonc.2020.554759. View

16.

Zhou C, Zhang W, Chen W, Yin Y, Atyah M, Liu S . Integrated Analysis of Copy Number Variations and Gene Expression Profiling in Hepatocellular carcinoma. Sci Rep. 2017; 7(1):10570. PMC: 5585301. DOI: 10.1038/s41598-017-11029-y. View

17.

Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View

18.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

19.

Reck M, Rabe K . Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):849-861. DOI: 10.1056/NEJMra1703413. View

20.

Li J, Chen Z, Tian L, Zhou C, He M, Gao Y . LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014; 63(11):1700-10. PMC: 4215280. DOI: 10.1136/gutjnl-2013-305806. View